Ziv-Aflibercept 25mg/ml Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV)
Available Strengths: 25mg/ml
Reference Brands: Zaltrap® (US & EU)
Category: Oncology Cancer Care
Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis. It targets vascular endothelial growth factor (VEGF), preventing tumor blood vessel growth. Available as an intravenous (IV) injection with a strength of 25 mg/mL, it is used in combination with chemotherapy for mCRC treatment. Ziv-aflibercept is available in both the US and EU, helping improve outcomes for patients with advanced colorectal cancer.
Product Description:
Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis – the process of new blood vessel formation that tumors need to grow. It works by targeting and binding to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with receptors on endothelial cells, thus blocking tumor blood vessel formation. Ziv-aflibercept is typically administered in combination with chemotherapy and is available in the US and EU in an intravenous (IV) formulation
Ziv-Aflibercept — third party manufacturing & bulk supply
Ziv-Aflibercept 25mg/ml is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Ziv-Aflibercept listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Ziv-Aflibercept →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Ziv‑aflibercept is used to treat certain types of cancers by inhibiting vascular endothelial growth factor (VEGF), which helps prevent the growth of new blood vessels that tumors need to grow. It is used in combination with chemotherapy for metastatic colorectal cancer and may be studied in other solid tumors.
The active ingredient is ziv‑aflibercept, a recombinant fusion protein that binds VEGF‑A, VEGF‑B, and placental growth factor (PlGF). It is formulated as a sterile solution for intravenous infusion.
The most recognized trade name for ziv‑aflibercept is Zaltrap®.
Ziv‑aflibercept is manufactured by Sanofi (Zaltrap®) and may also be produced by licensed generic or biosimilar manufacturers in regions where approved.
The generic (non‑proprietary) name is ziv‑aflibercept.
The brand name is Zaltrap®.
Ziv‑aflibercept is manufactured in GMP‑certified biopharmaceutical facilities globally, ensuring quality and safety for intravenous cancer therapy.
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
